The promise of GLP-1 drugs has always depended on people being able to afford them. These drugs still cost hundreds of dollars per month if you\u2019re paying cash, at which point access becomes a privilege: The higher-income executive who wants to trim a few pounds might be able to afford them either way, but the low-income worker who needs the drug to lose significant weight might not be able to afford them \u2014 unless their health insurance covers it.<\/p>\n
For a while, the trend lines for GLP-1 insurance coverage were positive. As of 2026, roughly two-thirds of private employer plans, which insure half of Americans, were covering GLP-1 medications for weight loss to treat obesity. Over the summer, Medicare launched<\/a> a new $50-per-month prescription program. The US has struggled with an obesity epidemic for decades, but it looked like powerful drugs to treat it were finally starting to be more seamlessly integrated into the health system.<\/p>\n At least that\u2019s how things appeared earlier this year. But now, private plans are pulling back from GLP-1 coverage. People are being left in the lurch, debating whether to try to pay for these drugs on their own or stop taking medicines they feel are making a real difference for their health.<\/p>\n The dilemma reveals one of the structural flaws in American healthcare. For working-age adults, your insurance depends on your job<\/a>. Unfortunately, because people no longer stay at the same job for decades, there is not a strong financial incentive for employers to make investments that will benefit your health in the long term \u2014 but there is a strong incentive to minimize short-term costs as much as possible. It\u2019s the kind of perverse rationale that could compel employer-sponsored health plans to stop covering a drug that, if taken over the full course of a person\u2019s life, could help them not only lose weight but ultimately reduce their risk of heart disease, kidney disease and other chronic health problems<\/a>, improving their health and saving all of us money as they get older.<\/p>\n \u201cAn employer or an insurer making coverage decisions doesn\u2019t necessarily care if they\u2019re saving Medicare money,\u201d said Dan Sacks<\/a>, a healthcare economist at the University of Wisconsin-Madison. \u201cThat\u2019s a classic problem with the American health insurance system, and it\u2019s certainly salient here.\u201d<\/p>\n This mismatch between what\u2019s good for people\u2019s health and what\u2019s good for the corporate bottom line has long been one of the underlying flaws in the US health system. Now access to GLP-1 drugs is shrinking just as these drugs were starting to make a real dent<\/a> in the US obesity crisis. The stakes couldn\u2019t be higher.<\/p>\n Why employer-sponsored health plans are suddenly dropping GLP-1 coverage<\/p>\n From the beginning<\/a>, insurance coverage was the big question hanging over GLP-1s and their potential to revolutionize US healthcare. But recently, it looked like we\u2019d turned a corner.<\/p>\n When I attended the Aspen Ideas: Health festival over the summer, pharmaceutical reps seemed visibly relieved that GLP-1 coverage had been picking up among private insurers. In 2026, about two out of every three employer-sponsored plans were covering some of these drugs for weight management, up from about 20 percent just the year before.<\/p>\n \u201cThey\u2019re recognizing that this is an investment in their workforce,\u201d said Laura Steele, who leads the cardiometabolic health unit at Eli Lilly, which manufactures Zepbound and Foundayo. \u201cYes, there is a budget, and there is a benefit design that every employer has. That\u2019s real. That\u2019s not going away. But they\u2019re also recognizing the overall cost that they\u2019re experiencing by not dealing with this too.\u201d<\/p>\n But as employers and private insurers make coverage decisions for next year, they are suddenly pulling back. At least 10 percent of employer plans that currently cover GLP-1s for weight loss say they are likely to discontinue coverage in 2027, according to one survey by the Business Group on Health<\/a> \u2014 and that number may still increase. A Mercer survey<\/a> of large employers found that 6 percent had dropped coverage in 2026 and another 5 percent were planning to in 2027 or actively considering it. A separate report from the Health Policy Commission in Massachusetts found<\/a> that the number of commercially insured people in the state taking a GLP-1 drug had fallen by 50 percent between 2025 and the first quarter of 2026 as private coverage started to drop off.<\/p>\n Some of the biggest brands in the US are reportedly eliminating or reducing their coverage: PepsiCo<\/a>, Starbucks<\/a>, and Lowe\u2019s<\/a> among them. And their reasons are simple: It\u2019s too expensive. The drugs still carry a high net price tag \u2014 $600 or more for a 30-day supply<\/a> \u2014 and potential demand is high (two in every five American adults<\/a> have obesity).<\/p>\n When a lot of people start taking an expensive medication all at once, it\u2019s going to raise costs for employer insurance plans \u2014 and they have to figure out how to adapt. Insurers set premiums at the start of each year, based on how many people are on the plan and how much healthcare they are expected to need. But if those estimates are off \u2014 say, if more people take an expensive GLP-1 drug than the insurer expected \u2014 they have to offset those costs somehow, and raising premiums the following year is a common solution. According to one estimate, premiums are projected<\/a> to grow by 5 to 13 percent due to GLP-1 costs \u2014 and the burden of paying those higher premiums is likely to fall on the workers<\/a>. The employer can also try to limit GLP-1 use by, for example, asking workers to pay more out of pocket for these drugs; according to Mercer<\/a>, 27 percent of large US employers instituted some kind of utilization controls for GLP-1 drugs over the past year or plan to next year.<\/p>\n They also have the option to simply stop covering these drugs for weight loss altogether \u2014 and that\u2019s the route more and more of them are deciding to take. The abrupt reversal has even caught economists like Sacks off guard.<\/p>\n 3 big reasons employer health plans are dropping GLP-1 coverage<\/p>\n Employers aren\u2019t invested in people\u2019s long-term health: As Americans switch jobs more often, companies want to cut short-term costs.GLP-1 prices are still high, upward of $600 per month per person for insurers.A lot of people are eligible to take them for weight loss; two in five US adults have obesity.<\/p>\n \u201cI was surprised that anyone would do an about-face because I thought they understood the trade-offs well,\u201d Sacks said. \u201cMy guess is that it turned out to be more expensive than they anticipated: Take-up is higher, and possibly more people are sticking with it. That\u2019s one reason that you might not want to continue to offer it.\u201d<\/p>\n For employers, the short-term costs of covering a drug often outweigh the long-term benefits that medication may confer, at least from the employer\u2019s POV. One analysis \u2014 notably produced by Blue Cross Blue Shield Kansas \u2014 concluded<\/a> that covering GLP-1s for weight loss increased average employee health costs by $7,000 in the first year and another $4,200 in the second, largely due to the cost of the drugs themselves. And yet at the same time, there were no decreases in obesity-related medical events in that time period. Another study<\/a> from Sacks and his colleagues at Indiana University and the University of South Carolina found that GLP-1 use did not lead to any cost savings over five years.<\/p>\n So in the short term, these employers are arguably making an economically rational decision \u2014 but one that may still come at their employees\u2019 expense. \u201cI\u2019m completely screwed,\u201d said<\/a> one person on Reddit about Cigna\u2019s plans<\/a> to drop GLP-1 coverage for their own employees. They\u2019re looking at at least $300 for one month\u2019s supply at cash prices.<\/p>\n They weren\u2019t alone either: \u201cI\u2019m devastated,\u201d said<\/a> another person, commenting on Starbucks\u2019s decision<\/a> to stop covering GLP-1 drugs. They said they had an autoimmune condition that had made it difficult to lose weight \u2014 until this new class of medicines came along.<\/p>\n Where GLP-1 coverage goes from here<\/p>\n How could we end up here, where it makes good business sense for companies to make a decision that could potentially harm their workers\u2019 health in the long term? It is at least in part a result of the haphazard way the US has ended up insuring people.<\/p>\n When employer-sponsored insurance started to arise in the mid-20th century<\/a>, eventually becoming the primary way to cover the working-age population, people tended to stay at the same job for a long period of time. In theory, there was a synergy: Companies wanted their workers to stay productive, and so it was worth it for the company to invest in their long-term health via their insurance benefits. And research has found<\/a> that people who stay with the same company \u2014 and the same insurance plan \u2014 tend to have better health than those who switch a lot.<\/p>\n But these days, people change jobs all the time or work various gigs<\/a> to piece together an income. You probably don\u2019t expect to stay at your job for 10 years \u2014 and your employer doesn\u2019t expect you to either. Instead, they want to keep their own costs as low as possible in the short term. This leads them to cut GLP-1 coverage, even though doctors do believe<\/a> that people could benefit tremendously long term from the weight loss these drugs help them achieve and all of its potential health benefits.<\/p>\n \u201cThere are very real health benefits of these drugs,\u201d Sacks told me. \u201cThe fact that we don\u2019t find offsets or they\u2019re even more expensive than we thought doesn\u2019t necessarily mean that we shouldn\u2019t cover them.\u201d<\/p>\n Sign up for the Good Medicine newsletter<\/p>\n Our political wellness landscape has shifted: new leaders, shady science, contradictory advice, broken trust, and overwhelming systems. How is anyone supposed to make sense of it all? Vox\u2019s senior correspondent Dylan Scott<\/a> has been on the health beat for a long time, and every week, he\u2019ll wade into sticky debates, answer fair questions, and contextualize what\u2019s happening in American healthcare policy. Sign up here<\/a>.<\/p>\n In theory, the market is supposed to fix the price problem: Drug companies get a period of exclusivity for the drugs they develop, and then, once that time elapses, cheaper generic versions can come onto the market. But generic semaglutide won\u2019t be available in the US until at least 2031<\/a> \u2014 and for some versions, the generic competitors aren\u2019t going to debut until the 2040s<\/a>. Offering GLP-1 coverage could become a competitive advantage for employers, a perk they can offer to entice potential workers as part of their benefits package.<\/p>\n Beyond that, though, the path to more affordable GLP-1s is not immediately obvious right now. A lot of people are already willing to pay cash for these drugs \u2014 and that may continue as long as people can afford to do it. But with inflation still steadily rising, these drugs could slip out of reach for more and more Americans.<\/p>\n The government could get involved, but, for now, the federal government\u2019s negotiating authority only covers Medicare, not the private plans that are dropping coverage. Serious healthcare reform is probably off the table until at least 2028, and then only if Democrats win both Congress and the White House and decide to make a healthcare package their legislative priority.<\/p>\n